The addition of the progestogen megestrol to letrozole significantly outperformed aromatase inhibitor monotherapy in reducing tumor proliferation markers (Ki67).
Genomic analysis demonstrated that megestrol reprograms estrogen receptor (ER) binding, effectively reducing transcriptional activity at canonical ER binding sites.
Low-dose megestrol (40 mg) showed potential as a dual-action agent: enhancing antiproliferative effects while potentially alleviating aromatase inhibitor-induced vasomotor symptoms.
The Evolving Role of Progesterone in Breast Cancer
